Juvabis AG
Next generation of antibacterial therapeutics
Juvabis is a clinical-stage biopharmaceutical startup that develops next-generation antimicrobial therapeutics against highly drug resistant infections. Juvabis holds an exclusive worldwide license for a strong IP portfolio invented at the ETH and University of Zurich by its co-founders. Juvabis has the most advanced antibiotic asset within the Innovative Medicines Initiative ENABLE program, having advanced to Phase-1, first-in-human, clinical trials (scheduled to conclude early 2021). Juvabis currently offers the opportunity for investors to finance Phase 2 clinical trials for its lead asset, whilst advancing the company's preclinical pipeline.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
14.12.2020
Juvabis causes a stir with new antibiotic (startupticker.ch)
14.09.2020
Strong Swiss delegation at Bio Europe (startupticker.ch)
11.03.2020
W.A. de Vigier Award : Numerous Cleantech Startups in the Top 16 (startupticker.ch)
25.11.2019
Venture Leaders 2019 Teams Celebrated at the US Embassy in Switzerland (venturelab.swiss)
18.11.2019
Juvabis' fight against antimicrobial resistance continues in first in-human clinical trials (startupticker.ch)
No Jobs
Videos
SCSN 2019
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Juvabis AG
Next generation of antibacterial therapeutics
Website:
www.juvabis.com
Headquarter:
Zürich
Foundation Date:
June 2015
Technology:
- Biotech
Sectors:
- Biotech
- Drug development platforms
- Drug discovery
- Infection
- Small molecule drugs
Support received
